Literature DB >> 18977321

Reconstructing the disease model and epigenetic networks for MLL-AF4 leukemia.

Bernd B Zeisig1, Ngai Cheung, Jenny Yeung, Chi Wai Eric So.   

Abstract

The lack of a proper animal model has impeded understanding of the molecular mechanism of leukemia associated with the MLL-AF4 fusion. In this issue of Cancer Cell, Krivtsov et al. report a much-improved murine Mll-AF4 model and propose a molecular link with H3K79 methylation mediated by the histone methyltransferase DOT1L.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18977321     DOI: 10.1016/j.ccr.2008.10.008

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  7 in total

1.  Histone methyltransferase MLL1 regulates MDR1 transcription and chemoresistance.

Authors:  Hairong Huo; Pellegrino G Magro; E Christy Pietsch; Brijesh B Patel; Kathleen W Scotto
Journal:  Cancer Res       Date:  2010-09-22       Impact factor: 12.701

Review 2.  Chapter 5. Nuclear actin-related proteins in epigenetic control.

Authors:  Richard B Meagher; Muthugapatti K Kandasamy; Elizabeth C McKinney; Eileen Roy
Journal:  Int Rev Cell Mol Biol       Date:  2009       Impact factor: 6.813

Review 3.  Dynamics of epigenetic modifications in leukemia.

Authors:  Iris Uribesalgo; Luciano Di Croce
Journal:  Brief Funct Genomics       Date:  2011-01-21       Impact factor: 4.241

Review 4.  Modulation of epigenetic targets for anticancer therapy: clinicopathological relevance, structural data and drug discovery perspectives.

Authors:  Federico Andreoli; Arménio Jorge Moura Barbosa; Marco Daniele Parenti; Alberto Del Rio
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.310

Review 5.  Genetically engineered mouse models of human B-cell precursor leukemias.

Authors:  Julia Hauer; Arndt Borkhardt; Isidro Sánchez-García; César Cobaleda
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  SOX7 promotes the maintenance and proliferation of B cell precursor acute lymphoblastic cells.

Authors:  Sara Cuvertino; Genny Filiciotto; Ashish Masurekar; Vaskar Saha; Georges Lacaud; Valerie Kouskoff
Journal:  Oncotarget       Date:  2016-07-07

Review 7.  Epigenetic therapies by targeting aberrant histone methylome in AML: molecular mechanisms, current preclinical and clinical development.

Authors:  C T Tsai; C W E So
Journal:  Oncogene       Date:  2016-09-05       Impact factor: 9.867

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.